AI English summary of an SEC filing — figures as filed
Medtronic MDTThe company said Cardiovascular net sales for the 3-month and 9-month periods ended January 26, 2024 were $2.9 billion and $8.7 billion, respectively, up 6% for both periods from the prior year. It cited strong performance from Micra, TAVR and Perfusion as the main factors.
Key points
AI summaryThe company said Cardiovascular net sales for the 3-month and 9-month periods ended January 26, 2024 were $2.9 billion and $8.7 billion, respectively, up 6% for both periods from the prior year. It cited strong performance from Micra, TAVR and Perfusion as the main factors.
Medtronic said Neuroscience net sales for the 3-month and 9-month periods ended January 26, 2024 were $2.4 billion and $6.9 billion, respectively, up 5% for both periods from the prior year. The company cited growth in Spine & Biologics as the main factor and, for the 9-month period, growth in ENT as an additional factor.
The company said it had commercial paper outstanding of $1.0 billion as of January 26, 2024 and none as of April 28, 2023. The $3.5 billion syndicated Credit Facility had no amounts drawn as of either date and expires in December 2027.
The company said it performed its annual goodwill impairment test in the third quarter of fiscal 2024, as well as tests before and after aligning to its new reporting structure, and found no goodwill impairment. It also said there were no impairments of definite-lived intangible assets in the current period.
Key figures
Quarter ended January 26, 2024
- Revenue
- $8.1B
- Operating income
- $1.5B
- Net income
- $1.3B
- EPS
- $0.99
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Cardiovascular net sales: 3-month $2.9 billion, 9-month $8.7 billion
The company said Cardiovascular net sales for the 3-month and 9-month periods ended January 26, 2024 were $2.9 billion and $8.7 billion, respectively, up 6% for both periods from the prior year. It cited strong performance from Micra, TAVR and Perfusion as the main factors.
Source · Based on the MD&A text of the filing
Neuroscience net sales: 3-month $2.4 billion, 9-month $6.9 billion
Medtronic said Neuroscience net sales for the 3-month and 9-month periods ended January 26, 2024 were $2.4 billion and $6.9 billion, respectively, up 5% for both periods from the prior year. The company cited growth in Spine & Biologics as the main factor and, for the 9-month period, growth in ENT as an additional factor.
Source · Based on the MD&A text of the filing
Short-term borrowing: commercial paper $1.0 billion, credit facility undrawn
The company said it had commercial paper outstanding of $1.0 billion as of January 26, 2024 and none as of April 28, 2023. The $3.5 billion syndicated Credit Facility had no amounts drawn as of either date and expires in December 2027.
Source · Based on the MD&A text of the filing
Goodwill and intangibles: no impairment
The company said it performed its annual goodwill impairment test in the third quarter of fiscal 2024, as well as tests before and after aligning to its new reporting structure, and found no goodwill impairment. It also said there were no impairments of definite-lived intangible assets in the current period.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…